+10.6%
GSK vs AVAV
-67.9%
+78.5%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | AVAV | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.2% | +10.5% | -10.6% | -0.2% |
| 7D | +1.7% | -10.6% | +12.2% | +1.7% |
| 30D | +7.0% | -18.8% | +25.8% | +7.2% |
| 3M | -2.7% | -34.1% | +31.4% | -2.2% |
| 6M | +1.4% | -35.3% | +36.8% | +1.9% |
| YTD | +5.3% | -53.4% | +58.7% | +5.8% |
| 1Y | +10.6% | -65.6% | +76.3% | +12.1% |
| All | +10.6% | -67.9% | +78.5% | +12.1% |
Cumulative growth
Daily Returns
Daily percentage return beside AVAV.
Daily Out/Under-Performance
Portfolio return minus AVAV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × AVAV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded AVAV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling